<DOC>
	<DOCNO>NCT02644083</DOCNO>
	<brief_summary>The primary objective study test hypothesis DMF improve mitochondrial function brain people MS . The investigator assess mitochondrial function cerebral grey matter measure PCr ATP 31P magnetic resonance spectroscopy ( MRS ) NAA NAWM 1H MRS .</brief_summary>
	<brief_title>Tecfidera MRI Brain Energy MS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Diagnosis MS 2010 McDonald criterion Relapsing clinical course Ages 1855 Laboratory value allow initiation dimethyl fumarate ( Tecfidera ) Systemic disease associate cerebrovascular disease ( e.g . diabetes mellitus , hypertension , hyperlipidemia , coronary heart disease ) Treatment corticosteroid diseasemodifying therapy ( interferon beta , glatiramer acetate , natalizumab , fingolimod , teriflunomide ) within 30 day first baseline MRI scan . Treatment time mitoxantrone , cyclophosphamide , long act immunosuppressant Prior treatment great 1 month time DMF Inability tolerate MRI procedure Pregnant/breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>